✦ LIBER ✦

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes

✍ Scribed by Shuchita Singh; Sachin Sethi; Vivek Khanna; Biju Benjamin; Rajiv Kant; Jitendra Sattigeri; Vinay S Bansal; Pradip Kumar Bhatnagar; Joseph Alex Davis

Book ID: 113588838
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 732 KB
Volume: 652
Category: Article
ISSN: 0014-2999
DOI: 10.1016/j.ejphar.2010.06.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum to “RBx-0597, a potent, selectiv

Erratum to “RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes” [European Journal of Pharmacology 652 (1–3) (2011) 157–163]

✍ Shuchita Singh; Subhasis Roy; Sachin Sethi; Biju Benjamin; Sindhuja Sundaram; Vi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 90 KB

The asymmetric synthesis of Sitagliptin,

The asymmetric synthesis of Sitagliptin, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

✍ Liu, Feng (author);Yu, Wansheng (author);Ou, Wenhua (author);Wang, Xiaoke (autho 📂 Article 📅 2010 🏛 Scientific Reviews Ltd. 🌐 English ⚖ 141 KB

The asymmetric synthesis of Sitagliptin,

The asymmetric synthesis of Sitagliptin, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

✍ Liu, Feng (author);Yu, Wansheng (author);Ou, Wenhua (author);Wang, Xiaoke (autho 📂 Article 📅 2010 🏛 Scientific Reviews Ltd. 🌐 English ⚖ 141 KB

ChemInform Abstract: The Asymmetric Synt

ChemInform Abstract: The Asymmetric Synthesis of Sitagliptin, a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

✍ Feng Liu; Wansheng Yu; Wenhua Ou; Xiaoke Wang; Libo Ruan; Yiming Li; Xijiang Pen 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 23 KB 👁 1 views

## Abstract Key step in the improved synthetic pathway to sitagliptin (VII), a new DPP‐IV inhibitor for the treatment of type 2 diabetes mellitus, is an asymmetric Michael addition to give intermediate (IV).

ChemInform Abstract: Discovery of Carmeg

ChemInform Abstract: Discovery of Carmegliptin (I): A Potent and Long-Acting Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes.

✍ Patrizio Mattei; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 16 KB 👁 2 views

Dipeptidyl peptidase IV (DPP IV) inhibit

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

✍ Green, Brian D; Flatt, Peter R; Bailey, Clifford J 📂 Article 📅 2006 🏛 International Society of Diabetes and Vascular Dis 🌐 English ⚖ 120 KB